Posts tagged Canada
Profound Medical completes enrollment in TACT pivotal trial

Profound Medical (OTCQX:PRFMF; TSXV:PRN) has completed patient enrollment in the TACT pivotal study designed to further evaluate safety and efficacy of its TULSA-PRO medical device to ablate prostate tissue in patients with localized, organ-confined prostate cancer.

Read More
CIBC-favored health care stocks for 2018

For 2018, CIBC World Markets is recommending investors hold a basket of healthcare stocks that include a combination of more speculative small and midcap companies with selected large caps.

Read More
IntelGenx, Tetra to develop Dronabinol XL tablet

IntelGenx (OTCQX:IGXT; TSXV:IGX) and Tetra Bio-Pharma (CSE:TBP; OTC:GRPOF) signed a definitive agreement to develop and commercialize a drug product containing the cannabinoid, Dronabinol, for the management of anorexia and cancer chemotherapy-related pain.

Read More
IntelGenx, Tetra in development term sheet

IntelGenx (TSX-V:IGX; OTCQX:IGXT) and Tetra Bio-Pharma (CSE:TBP; OTC: GRPOF) announced the signing of a binding term sheet for the development and commercialization of a drug product containing dronabinol.

Read More
Mackie ups Profound Medical price target to $4.40

Mackie Research Capital raised its price target for Profound Medical (TSX-V:PRN) to $4.40 from $3.30 after the company reported third quarter results. The stock closed at $1 on Thursday.

Analyst Andre Uddin writes that his new valuation is based on applying a multiple of 4.2 times enterprise value to sales on a 2019 sales estimate to $86-million, discounted back by 50%.

Read More
New U.S. patent expands Mati's IP portfolio

Closely-held Mati Therapeutics has been granted a U.S. patent covering a method of providing a sustained drug release to an eye using a proprietary punctal plug design placed in the punctum (tear duct) over a treatment period. 

The patent, which expires in 2028, complements earlier issued U.S. patent claims directed to the proprietary punctal plug for non-invasive sustained delivery of topical drugs to the eye. The proprietary technology is used for multiple disease states with consistent, sustained efficacy.

Read More
Popular Science picks Titan’s Probuphine for “Best of What’s New” award

Titan Pharmaceuticals’ (NASDAQ: TTNP) Probuphine implant has been recognized as one of the "12 Most Important Innovations of the Year" in the health category in Popular Science's annual Best of What's New issue.

Probuphine, a subdermal implant developed using Titan's proprietary ProNeura technology, was approved by the FDA in May, becoming the first commercially available long-term maintenance treatment of opioid dependence in clinically stable patients on 8 mg or less a day of oral buprenorphine.

Read More
Knight takes stake in 3D Signatures

Knight Therapeutics (TSX:GUD) has closed on a $1-million equity investment in closely-held 3D Signatures, which has completed a business combination and public listing transaction.

3D is a personalized medicine company, with a proprietary software platform based on the three-dimensional analysis of telomere organization. The technology is supported by 16 clinical studies on over 1,500 patients on 13 different cancers and Alzheimer's disease.

Read More
Valeant to commercialize Contrave in Canada

Valeant Canada, a subsidiary of Valeant Pharmaceuticals International (NYSE, TSX: VRX), will commercialize Orexigen Therapeutics’ (NASDAQ:OREX) Contrave (naltrexone HCl / bupropion HCl extended release) in Canada.

Under the accord, Valeant will be responsible for obtaining Canadian regulatory approval and for all commercialization activity and expenses. Orexigen will supply Contrave tablets to Valeant Canada or its affiliates for an agreed transfer price and certain potential regulatory and sales milestone payments. Orexigen expects Valeant to file with Health Canada for regulatory approval by January 2017.

Read More
First patients treated with Titan Pharma’s Probuphine

The first 10 patients received treatment last week with Titan Pharmaceuticals’ (NASDAQ:TTNP) Probuphine implant of buprenorphine, following FDA approval on May 26.

ProbuphineProbuphine was developed using Titan’s long-term, continuous drug delivery platform, ProNeura, for the maintenance treatment of opioid dependence.

Read More
Rodman starts LabStyle Innovations at buy

Rodman & Renshaw has initiated coverage of LabStyle Innovations (NASDAQ:DRIO) with a “buy” rating and $12 price target. The stock closed at $5.40 on Friday.

LabStyle is an emerging digital health company focused on the monitoring and management of diabetes.

Read More
Stifel upgrades Exelixis to buy

Stifel has upgraded Exelixis (NASDAQ:EXEL) to “buy” from “hold” with a price target of $7. The stock closed at $4.05 on Friday.

Exelixis is developing small molecule therapies for the treatment of cancer and is focusing its development and commercialization efforts primarily on cabozantinib, an internally discovered inhibitor of multiple receptor tyrosine kinases.

Read More
Avivagen posts positive swine trial results in China

Avivagen (TSX-V:VIV) has reported positive results of a trial of OxC-beta Livestock as a feed additive for swine run by COFCO Nutrition and Health Research Institute (COFCO NHRI) of Beijing.

The trial evaluated OxC-beta’s effect on growth efficiency and health of pigs raised under local conditions during the post-weaning “starter” period. OxC-beta enhanced growth in the “starter” pigs in this trial, a result consistent with previously-reported trials in swine and broiler poultry.

Read More
Can-Fite submits Phase 3 RA trial protocol to EMA

Can-Fite BioPharma (NYSE MKT:CANF; TASE:CFBI) has submitted to the European Medicines Agency (EMA) a protocol design for a Phase 3 trial and registration plan for its lead compound, CF101, in the treatment of rheumatoid arthritis. The company previously had a pre-submission meeting with the EMA.

The global trial is expected to begin in either the second or third quarter of 2016. It will investigate the efficacy and safety of CF101 administered orally twice daily for 16 weeks to patients with active rheumatoid arthritis treated with conventional disease modifying drugs.

Read More